Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with <em>BRAF V600</em>-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.
Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients withBRAF V600
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More